PLASMAPHERESIS REDUCES PROTEINURIA AND SERUM CAPACITY TO INJURE GLOMERULI IN PATIENTS WITH RECURRENT FOCAL GLOMERULOSCLEROSIS

被引:204
作者
ARTERO, ML
SHARMA, R
SAVIN, VJ
VINCENTI, F
机构
[1] UNIV CALIF SAN FRANCISCO, MOFFITT HOSP 884, TRANSPLANT SERV, SAN FRANCISCO, CA 94143 USA
[2] UNIV TRIESTE, OSPEDALE CATTINARA, INST PATOL MED, TRIESTE, ITALY
[3] UNIV KANSAS, MED CTR, DIV NEPHROL & HYPERTENS, KANSAS CITY, KS 66103 USA
关键词
FOCAL GLOMERULOSCLEROSIS; NEPHROTIC SYNDROME; PLASMAPHERESIS;
D O I
10.1016/S0272-6386(12)80381-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To test the hypothesis that a circulating mediator is associated with recurrent idiopathic focal glomerulosclerosis (FGS), we studied the effect of plasmapheresis on reducing proteinuria in patients with the disease. An in vitro assay measured the capacity of sera before and after plasmapheresis to cause increased albumin permeability (Palbumin) in isolated rat glomeruli. Nine patients (five males aged 2 to 66 years) who underwent plasmapheresis for recurrent FGS were identified. Study variables included age, sex, time from diagnosis of recurrence to first pheresis, glomerular hyalinosis, complications, outcome, and proteinuria before and after plasmapheresis. Rat glomeruli were isolated in medium containing 4 g/dL bovine serum albumin, and Palbumin was determined from the change in glomerular volume in response to an albumin gradient after incubation of the glomeruli in a 1:50 dilution of patient serum. Plasmapheresis reduced proteinuria from a mean of 12 ± 7.46 g/24 hr to 5.1 ± 7.39 g/24 hr (P = 0.03). Six patients in whom the diagnosis was made early in the course of the disease and in whom plasmapheresis was initiated immediately had lasting remissions. Preplasmapheresis biopsies in the patients who did not achieve remissions showed both epithelial foot process effacement and glomerular sclerosis. Serum samples were available from four patients for albumin testing in vitro. Palbumin was reduced from a mean of 0.76 ± 0.17 before pheresis to 0.18 ± 0.31 after (P = 0.07). Therefore, the mechanism by which plasmapheresis reduces proteinuria in patients with recurrent FGS involves the decreased capacity of sera from these patients to injure the glomerular permeability barrier. Plasmapheresis is likely to be effective in the therapy of recurrent FGS if the diagnosis is made promptly following the appearance of proteinuria, there is no significant hyalinosis on preplasmapheresis biopsy, and plasmapheresis is initiated immediately. © 1994, National Kidney Foundation. All rights reserved. All rights reserved.
引用
收藏
页码:574 / 581
页数:8
相关论文
共 29 条
  • [1] ARTERO M, 1991, Journal of the American Society of Nephrology, V2, P791
  • [2] RECURRENT FOCAL GLOMERULOSCLEROSIS - NATURAL-HISTORY AND RESPONSE TO THERAPY
    ARTERO, M
    BIAVA, C
    AMEND, W
    TOMLANOVICH, S
    VINCENTI, F
    [J]. AMERICAN JOURNAL OF MEDICINE, 1992, 92 (04) : 375 - 383
  • [3] THE RECURRENCE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN KIDNEY-TRANSPLANT PATIENTS TREATED WITH CYCLOSPORINE
    BANFI, G
    COLTURI, C
    MONTAGNINO, G
    PONTICELLI, C
    [J]. TRANSPLANTATION, 1990, 50 (04) : 594 - 596
  • [4] DISTINGUISHING MINIMAL-CHANGE DISEASE FROM MESANGIAL DISORDERS
    BORDER, WA
    [J]. KIDNEY INTERNATIONAL, 1988, 34 (03) : 419 - 434
  • [5] DESPERATE DISEASES AND PLASMAPHERESIS
    CAMPION, EW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (21) : 1425 - 1427
  • [6] RECURRENT NEPHROTIC SYNDROME FOLLOWING RENAL-TRANSPLANTATION IN PATIENTS WITH FOCAL GLOMERULOSCLEROSIS - A ONE-CENTER STUDY OF PLASMA-EXCHANGE EFFECTS
    DANTAL, J
    BAATARD, R
    HOURMANT, M
    CANTAROVICH, D
    BUZELIN, F
    SOULILLOU, JP
    [J]. TRANSPLANTATION, 1991, 52 (05) : 827 - 831
  • [7] DISAPPEARANCE OF PROTEINURIA AFTER IMMUNOADSORPTION IN A PATIENT WITH FOCAL GLOMERULOSCLEROSIS
    DANTAL, J
    TESTA, A
    BIGOT, E
    SOULILLOU, JP
    [J]. LANCET, 1990, 336 (8708) : 190 - 190
  • [8] CYCLOSPORINE, LOW-DENSITY LIPOPROTEIN, AND CHOLESTEROL
    DEGROEN, PC
    [J]. MAYO CLINIC PROCEEDINGS, 1988, 63 (10) : 1012 - 1021
  • [9] Habib R, 1987, Contrib Nephrol, V55, P123
  • [10] HOYER JR, 1972, LANCET, V2, P343